RxDoctor Payments Data

Coromoto Palermo, MD

Endocrinology, Diabetes & Metabolism · Pembroke Pines, FLNPI 1629271184

Payments from drug & device makers

$30,551in general payments, 2019–2025

Across 940 payments — averaging $32.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$12K
  • Lilly USA, LLC$3K
  • Novo Nordisk$2K
  • Medtronic$2K
  • Insulet Corporation$1K
  • Boehringer Ingelheim$1K
  • plus $10K from 44 others

What the payments were for

  • Consulting fees$2,0007%
  • Speaking & faculty fees$6,46421%
  • Travel & lodging$1,7646%
  • Food & beverage$20,12466%
  • Education$2001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,551 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$21,995
Medicare patients
77
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin212$317,670
MounjaroTirzepatide158$253,148
OzempicSemaglutide166$247,099
Soliqua 100-33Insulin Glargine/Lixisenatide97$122,024
FarxigaDapagliflozin Propanediol77$103,366
TrulicityDulaglutide47$75,827
ProliaDenosumab30$52,666
RybelsusSemaglutide31$51,197
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/738$42,797
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog50$41,668
AfrezzaInsulin Regular, Human19$32,350
XyostedTestosterone Enanthate16$27,683
JanuviaSitagliptin Phosphate19$26,360
Novolog FlexpenInsulin Aspart71$25,335
Tresiba Flextouch U-200Insulin Degludec29$23,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$1,259$357,462241 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$2,604$331,184217 claims
Novo NordiskOzempic, Rybelsus, Fiasp, Novolog$1,793$318,249234 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$1,232$122,02497 claims
AstraZenecaFarxiga$882$103,36677 claims
AmgenProlia$11,653$52,66630 claims
MerckJanuvia, Janumet Xr$195$41,05330 claims
Mannkind CorporationAfrezza$884$32,35019 claims
Antares Pharma, Inc.Xyosted$225$27,68316 claims
Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium$313$12,804354 claims
AbbVieSynthroid, Armour Thyroid$513$7,71585 claims
Cequr CorporationCequr Simplicity$387$6,51211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →